RT Journal Article
SR Electronic
T1 Y380Q novel mutation in receptor-binding domain of SARS-CoV-2 spike protein together with C379W interfere in the neutralizing antibodies interaction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.10.21262695
DO 10.1101/2021.09.10.21262695
A1 Sauthier Sartor, Ivaine Tais
A1 Varela, Fernanda Hammes
A1 Meireles, Mariana Rost
A1 Kern, Luciane Beatriz
A1 Azevedo, Thaís Raupp
A1 Tumioto Giannini, Gabriela Luchiari
A1 da Silva, Mariana Soares
A1 Demoliner, Meriane
A1 Gularte, Juliana Schons
A1 de Almeida, Paula Rodrigues
A1 Fleck, Juliane Deise
A1 Zavaglia, Gabriela Oliveira
A1 Fernandes, Ingrid Rodrigues
A1 de David, Caroline Nespolo
A1 Santos, Amanda Paz
A1 de Almeida, Walquiria Aparecida Ferreira
A1 Gomes Porto, Victor Bertollo
A1 Scotta, Marcelo Comerlato
A1 Vieira, Gustavo Fioravanti
A1 Spilki, Fernando R.
A1 Stein, Renato T.
A1 Polese-Bonatto, Márcia
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/09/14/2021.09.10.21262695.abstract
AB Background The emergence of SARS-CoV-2 variants is a current public health concern possibly impacting COVID-19 disease diagnosis, transmission patterns and vaccine effectiveness.Objectives To describe the SARS-CoV-2 lineages circulating early pandemic among samples with S gene dropout and characterize a novel mutation in receptor-binding domain (RBD) of viral spike protein.Study design Adults and children older than 2 months with signs and symptoms of COVID-19 were prospectively enrolled from May to October 2020 in Porto Alegre, Brazil. All participants performed RT-PCR assays for diagnosing SARS-CoV-2, samples with S gene dropout and Ct < 30 (cycle threshold) were submitted to whole genome sequencing (WGS), and homology modeling and physicochemical properties analysis were performed.Results 484/1,557 participants tested positive for SARS-CoV-2. The S gene dropout was detected in 7.4% (36/484) as early as May, and a peak was observed in early August. WGS was performed in 8 samples. The B.1.1.28, B.1.91 and B.1.1.33 lineages were circulating in early pandemic. The RBD novel mutation (Y380Q) was found in one sample occurring simultaneously with C379W and V395A, and the B.1.91 lineage in the spike protein.Conclusion Mutations in the SARS-CoV-2 spike region were detected early in the COVID-19 pandemic in Southern Brazil, regarding the B.1.1.28, B.1.91 and B.1.1.33 lineages identified. The novel mutation (Y380Q) with C379W, modifies important RBD properties, which may interfere with the binding of neutralizing antibodies (CR3022, EY6A, H014, S304).HighlightsCharacterization of novel mutation (Y380Q) in RBD of SARS-CoV-2 spike proteinThe Y380Q and C379W modify important properties in the SARS-CoV-2 RBD regionThe RBD mutations may interfere with the binding of neutralizing antibodiesThe B.1.1.28, B.1.91 and B.1.1.33 lineages were circulating in early pandemicCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Brazilian Ministry of Health, through the Institutional Development Program of the Brazilian National Health System (PROADI-SUS) in collaboration with Hospital Moinhos de Vento.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was performed in accordance with the Decree 466/12 of the National Health Council and Clinical Practice Guidelines, after approval by the Hospital Moinhos de Vento IRB number: 4.637.933. All participants included in this study provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript and in the supplementary material.